Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance

[1] Neer RM(2001)Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434-1441

[2] Arnaud CD(2007)Non-compliance: the Achilles’ heel of anti-fracture efficacy Osteoporos Int 18 711-719

[3] Zanchetta JR(2004)The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003-1008

[4] Prince R(2006)Determinants of adherence to osteoporosis treatments in clinical practice Osteoporos Intl 17 914-921

[5] Gaich GA(2006)Compliance with drug therapy for postmenopausal osteoporosis Osteoporos Int 17 1645-1652

[6] Reginster JY(2006)Persistence with teriparatide in patients with osteoporosis: the UK experience Osteoporos Int 17 1626-1629

[7] Hodsman AB(2009)Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience Osteoporos Int 20 625-630

[8] Eriksen EF(2008)Characteristics of patients initiating teriparatide for the treatment of osteoporosis Osteoporos Int 19 373-377

[9] Ish-Shalom S(2007)Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 1493-1501

[10] Genant HK(2005)Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453-1460

[1] Neer RM(2001)Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434-1441

[2] Arnaud CD(2007)Non-compliance: the Achilles’ heel of anti-fracture efficacy Osteoporos Int 18 711-719

[3] Zanchetta JR(2004)The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003-1008

[4] Prince R(2006)Determinants of adherence to osteoporosis treatments in clinical practice Osteoporos Intl 17 914-921

[5] Gaich GA(2006)Compliance with drug therapy for postmenopausal osteoporosis Osteoporos Int 17 1645-1652

[6] Reginster JY(2006)Persistence with teriparatide in patients with osteoporosis: the UK experience Osteoporos Int 17 1626-1629

[7] Hodsman AB(2009)Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience Osteoporos Int 20 625-630

[8] Eriksen EF(2008)Characteristics of patients initiating teriparatide for the treatment of osteoporosis Osteoporos Int 19 373-377

[9] Ish-Shalom S(2007)Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 1493-1501

[10] Genant HK(2005)Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453-1460